Oncology Medical News about celecoxib, neuroblastoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts
Cancer Science, 08/12/09

Kaneko M et al. - In a study to evaluate antitumor effect of irinotecan (CPT-11) treatment combined with prolonged very low-dose administration of celecoxib against 3 human neuroblastoma (NB) xenografts, TNB9, TS-N-2nu, and TS-N-5nu, it was shown that prolonged low-dose CPT-11 treatment combined with very low-dose celecoxib has promising antitumor activity through the blockage of multiple critical targets related to NB tumor cell survival and proliferation.

Methods

The effects of the celecoxib-combined treatment were examined on tumor cell proliferation, apoptosis, angiogenesis, and expression of vascular endothelial growth factor and apoptosis-related proteins in xenografts.
Antitumor effect of CPT-11 treatment combined with prolonged very low-dose administration of celecoxib was evaluated against 3 human NB xenografts, TNB9, TS-N-2nu, and TS-N-5nu.

Results

Celecoxib administered daily at 5 mg/kg body weight/day could not prevent growth of any of the NB xenografts; but the combination of daily low-dose CPT-11 (5.9 mg/kg body weight/day) and simultaneous very low-dose celecoxib resulted in highly significant suppression of tumor growth in all 3 xenografts compared not only with low-dose CPT-11 therapy alone but also with combination therapy of intermittent conventional-dose CPT-11 (59 mg/kg body weight) and celecoxib accompanied by decreased proliferation and increased induction of apoptosis in tumor cells.
Induction of apoptosis by CPT-11 with and without celecoxib was associated with up-regulation of Bax expression and down-regulation of Bcl-2 expression.
Enhanced antitumor effect of the combination against NB xenografts might be partially COX-2-independent and was probably mediated through multiple factors including diminished expression of VEGF and activation of caspase-dependent mitochondrial apoptosis pathway.

<< Previous
Clinical relevance of neuroendocrine differentiation in non-small...

Next >>
Expression and significance of EGFR in malignant peripheral nerve...